Condition
Venom Allergy
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 4 (2)
Trial Status
Recruiting2
Not Yet Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06935890Phase 4Recruiting
Jack Jumper Ant Venom Immunotherapy Long-term Effectiveness Investigation
NCT07328178Recruiting
Analysis of the Role of IgE Proteoforms in Health and Disease
NCT06876506Not Yet Recruiting
Identification of B Regulatory Cells by Flow Cytometry
NCT00684476Phase 4CompletedPrimary
Maintenance Bee-Venom Immunotherapy Administered at 6-Month Intervals Does Not Protect Against re-Stings
Showing all 4 trials